the sustained release form of mexiletine ( mexitil-perlongets ) , 360 mg b.i.d. , was evaluated for antiarrhythmic efficacy in a double-blind placebo trial in 630 patients with recent documented myocardial infarction .
C0025887
mexiletine
C0003195
antiarrhythmic